TCTR20210921002招募中不适用
Safety and Immunogenicity of adenovirus vector COVID-19 vaccines for radiotherapy patients in Thailand
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1) Age greater than or equal to 18 years
- •2) ECOG Performance status 0-2
- •3) Well-controlled underlying disease
- •4) Life expectancy 6 months or more
- •5) was diagnosed with a solid cancer or a tumor that requires radiation therapy or radiation in combination with chemotherapy drugs with at least 10 radiation plans
- •6) Voluntarily receive the Astrazeneca COVID-19 vaccine.
- •7) Voluntarily join the program with written consent.
排除标准
- •1) Immunodeficiency conditions such as HIV infection or congenital immunodeficiency syndrome
- •2) A history of COVID-19 infection or a nucleocapsid protein IgG antibodies test before the first dose of vaccination has a positive result indicating a natural infection.
- •3) There is a radiation plan for total body irradiation (TBI), total lymphoid irradiation (TLI), craniospinal irradiation (CSI).
- •4) Receive chemotherapy drugs taken before radiation within 4 weeks (induction or palliative chemotherapy).
- •5) have received radiation before (previous radiotherapy)
- •6) Pregnant women
研究者
相似试验
招募中
不适用
Safety and Immunogenicity of adenovirus vector COVID-19 vaccines following with additional dose of mRNA COVID-19 vaccines for cancer patients.COVID19 Vaccine efficacy in oncologic patient.viral vector vaccine , mRAN vaccinecancer patientsafety and immunogenicityTCTR20220112004Quality Improvement fund, King chulalongkorn Memorial Hospital,The Thai Red Cross Society400
进行中（未招募）
不适用
Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster DoseHepatitis AEUCTR2015-005191-18-Outside-EU/EEASanofi Pasteur SA720
尚未招募
1 期
CENTAURO-6 StudyLiver NeoplasmsCarcinoma, HepatocellularDigestive System NeoplasmsLiver DiseasesDigestive System DiseasesAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialHepatocellular carcinomaRPCEC00000237Center for Genetic Engineering and Biotechnology (CIGB), in Havana.20
Unknown
3 期
Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older.COVID-19PACTR20201152310190334,520
已完成
不适用
Safety and efficacy of cidofovir for adenovirus infectioadenovirus infectionJPRN-UMIN000004336Hematology, Osaka City University, Graduate School of Meicine21